DocMorris Q1 Revenue Rises 10.7% to CHF318.1m

DocMorris AG posted Q1 2026 revenue of CHF318.1 million, up 10.7% year‑over‑year in local currency.
German prescription sales jumped 26.4% YoY to CHF68.1 million, aided by bonus co‑payment incentives rolled out in March.
Active users reached 12.6 million, a 3.3% QoQ rise; non‑prescription sales grew 3.3% YoY (6.5% local) with digital services up 63.1%.
Adjusted EBITDA improved to a CHF6.3 million loss; guidance targets low‑teens revenue growth and EBITDA between –CHF10 m and –CHF25 m, aiming break‑even by Q4.